ORGANOGENESIS HOLDINGS INC. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent
ORGANOGENESIS HOLDINGS INC. (ORGO) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent of 1.30% for the 12-month period ending 2022-12-31, per its 10-K filed 2023-03-01.
Discontinued › Expense Statement › Income Tax
us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense · last filed 2023-03-01
- ORGANOGENESIS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2022 was 1.30%, a 62.50% increase from fiscal 2021.
- ORGANOGENESIS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2021 was 0.80%, a 86.67% decline from fiscal 2020.
- ORGANOGENESIS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2020 was 6.00%.
- ORGANOGENESIS HOLDINGS INC. effective income tax rate reconciliation, nondeductible expense, percent for fiscal 2019 was -1.40%.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent 12 month |
|---|---|
| 2022-12-31 | 1.30% 10-K · filed 2023-03-01 |
| 2021-12-31 | 0.80% 10-K · filed 2023-03-01 |
| 2020-12-31 | 6.00% 10-K · filed 2023-03-01 |
| 2019-12-31 | -1.40% 10-K · filed 2022-03-01 |
| 2018-12-31 | -2.30% 10-K · filed 2021-03-16 |
| 2017-12-31 | -6.80% 10-K · filed 2020-03-09 |
| 2016-12-31 | -3.20% 10-K · filed 2019-03-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 | |
| LIFECORE BIOMEDICAL, INC. DE (LFCR) | United States | $0.163B | -8.50 |